H. Braak and K. Del Tredici 1

H. Braak and K. Del Tredici 1

Supplementary References

e1. Forno LS. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996;55:259-272.

e2. Poewe W, Wenning G. The natural history of Parkinson’s disease. Ann Neurol 1998;44(3 suppl 1):S1-9.

e3. Jellinger KA, Mizuno Y. Parkinson's disease. In: Dickson DW, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropathologica Press; 2003:159-187.

e4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.

e5. Bennet DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.

e6. Calne DB, Mizuno Y. The neuromythology of Parkinson’s disease. Parkinsonism Rel Disord 2004;10:319-322.

e7. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson’s disease. J Neural Transm 2006;70(suppl):147-151.

e8. Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson’s disease. Hum Mol Genet 1997;6:1687-1691.

e9. Giasson BI, Covy JP, Bonini NM, et al. Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006;59:315-322.

e10. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson’s disease. Neuropathologic considerations. Adv Neurol 1993;60:600-608.

e11. Bower JH, Maraganore DM, Peterson BJ, McDonell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. Neurology 2003;60:1610-1615.

e12. Sibon I, Tison F. Vascular parkinsonism. Curr Opin Neurol 2004;17:49-54.

e13. Kamel F, Tanner C, Umbach D, et al. Pesticide exposure and self-reported Parkinson’s disease in the agricultural health study. Am J Epidemiol 2007;165:364-374.

e14. Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007;86:112-121.

e15. Dickson DW, Litvan I. Corticobasal degeneration. In: Dickson DW, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropathologica Press; 2003:115-123.

e16. Duyckaerts C. Atypical Parkinsonian disorders: neuropathology and nosology. In: Litvan I, editor. Current Clinical Neurology: Atypical Parkinsonian Disorders. Totowa NJ: Humana Press; 2005:111-138.

e17. Dickson DW, Rademachers R, Nutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007;17:74-82.

e18. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 1998;31:205-208.

e19. Lantos PL, Quinn N. Multiple system atrophy. In: Dickson, DW, editor. Neurodegeneration: The Molecular Pathology od Dementia and Movement Disorders. Basel: ISN Neuropathologica Press; 2003:203-214.

e20. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropath Appl Neurobiol 2007;33:615-620.

e21. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol 1997;94:192-196.

e22. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. -Synuclein in Lewy bodies. Nature 1997;388:839-840.

e23. Arai K, Kato N, Kashiwado K, Hattori. T Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 2000;296:171-173.

e24. Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial manifestation of Parkinson’s disease and dementia with Lewy bodies. Neurology 2004;63:1093-1095.

e25. Lavedan C. The synuclein family. Gen Res 1998;8:871-880.

e26. den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960;23:283-290.

e27. Takahashi H, Wakabayashi K. Controversy: is Parkinson’s disease a single disease entity? Yes. Parkinsonism Rel Disord 2005;11:31-37.

e28. Braak H, Müller CM, Bohl JR, Rüb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson disease reconsidered. Mov Disord2006;21:2042-2051.

e29 Gibb WRG, Scott T, Lees AJ. Neuronal inclusions of Parkinson’s disease. Mov Disord 1991;6:2-11.

e30. Lowe J. Lewy bodies. In: Calne DP, editor. Neurodegenerative Diseases. Philadelphia: Saunders; 1994:51-69.

e31. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? Nat Med 1998;4: 755-757.

e32. Giasson BI, Galvin JE, Lee VM-Y, Trojanowski JQ. The cellular and molecular pathology of Parkinson’s disease. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. New York: McGraw Hill; 2000:219-228.

e33. Goldberg MS, Lansbury PT. Is there a cause-and-effect relationship between -synuclein fibrillization and Parkinson’s disease? Nat Cell Biol 2000;2:E115-E119.

e34. Jensen PH, Gai WP. Alpha-synuclein. Axonal transport, ligand interaction, and neurodegeneration. In: Tolnay M, Probst A, editors. Neuropathology and Genetics of Dementia. New York: Kluwer Academic/Plenum; 2001:129-134.

e35. Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteosome function. J Biol Chem 2003;278:44405-44411.

e36. Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord 2005;20:37-44.

e37. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord 2006;21:1806-1823.

e38. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol 2003;184(suppl 1):68-79.

e39. Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowl Environm 2004;23:1-13.

e40. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.

e41. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.

e42. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson’s disease? Neurology 1991;41(suppl 2):8-13.

e43. Dickson DW. Aging in the central nervous system. In: Markesbery WR, editor. Neuropathology of Dementing Disorders: London, New York: Arnold; 1998:56-88.

e44. Wolters EC, Braak H. Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm 2006;70(suppl):309-319.

e45. Hawkes CH, Shephard BC, Daniel SE. Is Parkinson’s disease a primary olfactory disorder? Q J Med 1999;92:473-480.

e46. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599-614.

e47. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer’s disease et al. Neuroscience 1987;23:389-398.

e48. Pearson RCA. Cortical connections and the pathology of Alzheimer’s disease. Neurogeneration 1996;5:429-434.

e49. Braak H, Del Tredici K. Poor and protracted myelination as a contributary factor to neurodegenerative disorders. Neurobiol Aging 2004;25:19-23.

e50. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;62:436-446.

e51 McBride PA, Schulz-Schaeffer WJ, Donaldson M, et al.Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol 2001;75:9320-9327.

e52. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa. Exp Neurol 1999;160:515-522.

e53. Huang XF, Törk I, Paxinos G. Dorsal motor nucleus of the vagus nerve: a cyto- and chemoarchitectonic study in the human. J Comp Neurol 1993;330:158-182.

e54. Hopkins DA, Bieger D, de Vente J, Steinbusch HWM. Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Progr Brain Res 1996;107:79-96.

e55. Saper CB, Sorrentino DM, German DC, de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson’s disease. Ann Neurol 1991;29:577-584.

e56. Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 1963;86:781-792.

e57. Costa M, Brookes SJH, Hennig GW. Anatomy and physiology of the enteric nervous system. Gut 2000;47(suppl 4):15-19.

e58. Anlauf M, Schäfer MKH, Eiden L, Weihe E. Chemical coding of the human gastroinstestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol 2003;459:90-111.

e59. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-583.

e60. Phillips RF, Powley TL. Innervation of the gastrointestinal tract: Patterns of aging. Auton Neurosci: Basic and Clinical 2007;136:1-19.

e61. Benarroch EE. Enteric nervous system: Functional organization and neurologic implications. Neurology 2007;69:1953-1957.

e62. Cersósimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008 (in press)

e63. Saper CB, Wainer BH, German DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience 1987;23:389-398.

e64. Pearson RCA. Cortical connections and the pathology of Alzheimer’s disease. Neurodegeneration 1996;5:429-434.

e65. Strack AM, Sawyer WB, Hughes JH, Platt KB, Loewy AD. A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections. Brain Res 1989;491:156-162.

e66. Card JP. Exploring brain circuitry with neurotropic viruses: new horizons in neuroanatomy. Anat Rec 1998;253:176-185.

e67. Morrison LA, Sidman RL, Fields BN. Direct spread of reovirus from the intestinal lumen to the central nervous system through vagal autonomic nerve fibers. Proc Natl Acad Sci USA 1991;88:3852-3856.

e68. Dobbs SM, Dobbs RJ, Weller C, Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Medical Hypotheses 2000;55:93-98.

e69. Casado B, Pannell LK, Iadarola P, Baraniuk JN. Identification of human nasal mucous proteins using proteomics. Proteomics 2005;5:2949-2959.

e70. Wakabayashi K, Takahashi H. The intermediolateral nucleus and Clarkes column in Parkinson’s disease. Acta Neuropathol 1997;94:287-289.

e71. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997;14:2-31.

e72. Loewy AD. Central autonomic pathways. In: Loewy AD, Spyer KM, editors. Central Regulation of Autonomic Functions. New York: Oxford University Press; 1990:88-103.

e73. Craig AD. An ascending general homeostatic afferent pathway originating in lamina I. Progr Brain Res 1996;107:225-242.

e74. Halliday GM. Substantia nigra and locus coeruleus. In: Paxinos G, Mai JK, editors. The Human Nervous System, 2nd ed. San Diego, London: Elsevier; 2004:449-463.

e75. Craig, AD. Pain mechanisms: labeled lines versus convergence in central processing. Ann Rev Neurosci 2003;26:1-30.

e76. Ford B. Pain in Parkinson’s disease. Clin Neurosci 1998;5:63-72.

e77. Gonera EG, van’t Hof M, Bergen HJ, van Weel C, Horstink MW. Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 1997;12:871-876.

e78. van Dongen PA. The human locus coeruleus in neurology and psychiatry. Progr Neurobiol 1981;17:97-139.

e79. Lu J, Sherman D, Devor M, Saper CB. A putative flip-flop switch for control of REM sleep. Nature 2006;44:589-594.

e80. Nieuwenhuys R. The greater limbic system, the emotional motor system and the brain. Progr Brain Res 1996;107:551-580.

e81. Holstege G, Mouton LJ, Gerrits NM. Emotional motor system. In: Paxinos G, Mai JK, editors. The Human Nervous System, 2nd ed. San Diego, London: Elsevier; 2004:1306-1325.

e82. Koutcherov Y, Huang XF, Halliday G,, Paxinos G. Organization of human brain stem nuclei. In: Paxinos G, Mai JK, editors. The Human Nervous System, 2nd edition. San Diego, London: Elsevier; 2004:273-321.

e83. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 1994;88:439-500.

e84. Bohus B, Koolhaas JM, Luiten PGM, Korte SM, Roozendaal B, Wiersma A. The neurobiology of the central nuleus of the amygdala in relation to neuroendocrine and autonomic outflow. Progr Brain Res 1996;107:447-460.

e85. Sims KS, Williams RS. The human amygdaloid complex: a cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorase staining. Neuroscience 1990;36:449-472.

e86. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 1992;15:6-31.

e87. Wakabayashi K, Hansen LA, Masliah E. Cortical Lewy body-containing neurons are pyramidal cells. Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 1995;89:404-408.

e88. Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000;100:285-290.

e89. Braak H, Rüb U, Jansen Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathological stage in Parkinson disease. Neurology 2005;64:1404-1410.

e90. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 2007;62:145-153.

e91. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Demonstration of -synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 2002;176:98-104.

e92. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 1995;20:91-127.

e93. Saper CB. Role of the cerebral cortex and striatum in emotional motor response. Progr Brain Res 1996;107:537-550.

e94. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteosome system in Parkinson’s disease. Nat Rev Neuroscience 2001;2:589-594.

e95. Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.

e96. Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated -synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644-654.

e97. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RAI, Del Tredici K. Pathology associated with sporadic Parkinson’s disease – where does it end? J Neural Transm 2006;70(suppl):89-97.

e98. Halliday GM, Del Tredici K, Braak H. Critical appraisal of the Braak staging of brain pathology related to sporadic Parkinson’s disease. J Neural Transm 2006;70(suppl):99-103.

e99. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:138-142.

e100. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004;56:173-181.

e101. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-1202.

e102. Stiasny-Kolster K, Doerr Y, Möller JC, Hoffken H, Behr TM, Oertel WH, Mayer G. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for -synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126-137.

e103. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 2006;22:839-842.

e104. Ross W, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk of future Parkinson’s disease. Ann Neurol 2008;63:167-173.

e105. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.

e106. Sato K, Yamashiro K, Kagohashi M, et al. Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 2006;21:1384-1395.

e107. Hawkes CH. Parkinson’s disease and aging: same or different process? Mov Disord 2008;23:47-53.